Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
32 Results for "
PDE9
" in MedChemExpress (MCE) Product Catalog:
Products (32)
32 Results for "PDE9" in MCE Product Catalog:
4
4 Cited Publications
4
Target:
Research Areas:
Edelinontrine (PF-04447943) is a potent inhibitor of human recombinant PDE9A (IC50=12 nM) with >78-fold selectivity, respectively, over other PDE family members (IC50>1000 nM).
2
2 Cited Publications
Target:
Research Areas:
BAY 73-6691 ((R)-BAY 73-6691) is a potent, brain penetrant, and selective PDE9A inhibitor .
1
Target:
Research Areas:
Osoresnontrine (BI-409306) is a potent and selective PDE9A inhibitor, with an IC50 of 52 nM, and shows weak activity against other PDEs, such as PDE1A (IC50, 1.4 µM), PDE1C (IC50, 1.0 µM), PDE2A, PDE3A, PDE4B, PDE5A, PDE6AB, PDE7A, and PDE10A (IC50 all > 10 μM); Osoresnontrine can be used in the research of memory enhancement in CNS disorders.
1
1 Cited Publications
Target:
Research Areas:
BAY-7081, a chemical probe, is a potent, selective, orally active and soluble cyanopyridone-based PDE9A inhibitor with an IC50 of 15 nM .
Synonyms: E2027
Target:
Research Areas:
Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine can be used for the research of neurological diseases .
Synonyms: IMR-687
Target:
Research Areas:
Tovinontrine (IMR-687) is a highly potent and selective phosphodiesterase-9 (PDE9) inhibitor specifically for the treatment of sickle cell disease. IC50s are 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively .
Target:
Research Areas:
(S)-C33 is a potent and selective PDE9 (phosphodiesterase-9) inhibitor, with an IC50 of 11 nM. (S)-C33 can be used for central nervous system diseases and diabetes research .
Cat. No.: HY-50865
CAS No.: 1082743-70-1
Target:
Research Areas:
PDE-9 inhibitor is a potent PDE-9 inhibitor. PDE-9 inhibitor can be used for neurodegenerative diseases, such as Alzheimer's disease and schizophrenia .
Synonyms: (R)-E2027
Target:
Research Areas:
(R)-Irsenontrine ((R)-E2027), the R-enantiomer of Irsenontrine (HY-132821), is a potent phosphodiesterase 9 (PDE9) inhibitor with an IC50 value of 0.041 μM. (R)-Irsenontrine can be used for the research of neurological diseases .
Target:
Research Areas:
PF-04449613 is a selective PDE9A inhibitor with an IC50 of 22 nM[1]. PF-04449613 improved motor learning ability in a mouse model[2].
Target:
Research Areas:
PDE9-IN-1 is a potent, selective, and orally bioavailable phosphodiesterase-9A (PDE9A) Inhibitor with an IC50 of 8.7 nM .
Cat. No.: HY-148625
CAS No.: 917089-10-2
Target:
Research Areas:
PDE9-IN-2 (compound 6) is a PDE9 inhibitor that improves heart failure.
Cat. No.: HY-132821A
CAS No.: 1630083-70-3
Synonyms: E2027 maleate
Target:
Research Areas:
Irsenontrine (E2027) maleate is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine maleate can be used for the research of neurological diseases .
Cat. No.: HY-114643
CAS No.: 1430840-90-6
Synonyms: (Rac)-IMR-687
Target:
Research Areas:
(Rac)-Tovinontrine ((Rac)-IMR-687) is a phosphodiesterase 9 (PDE9) inhibitor that increases cyclic guanosine monophosphate (cGMP) levels. (Rac)-Tovinontrine is promising for research of thalassemia .
Target:
Research Areas:
(S)-BAY 73-6691 is the isomer of BAY 73-6691 (HY-104028), and can be used as an experimental control. BAY 73-6691 ((R)-BAY 73-6691) is a potent, brain penetrant, and selective PDE9A inhibitor .
Cat. No.: HY-170435
Target:
Research Areas:
PDE5-IN-13 (Compound 14b) inhibits phosphodiesterase 5 (PDE5A) with an IC50 of 3 nM. PDE5-IN-13 is a potential candidate for PAH (pulmonary arterial hypertension) research. PDE5-IN-13 has high selectivity for targets over PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11. PDE5-IN-13 is orally active .
Cat. No.: HY-RS10246
Target:
Research Areas:
PDE9A Human Pre-designed siRNA Set A contains three designed siRNAs for PDE9A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS10247
Target:
Research Areas:
Pde9a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pde9a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS10248
Target:
Research Areas:
Pde9a Rat Pre-designed siRNA Set A contains three designed siRNAs for Pde9a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
